Get Newsletter
Alzheimer Research Forum - Networking for a Cure Alzheimer Research Forum - Networking for a CureAlzheimer Research Forum - Networking for a Cure
  
What's New HomeContact UsHow to CiteGet NewsletterBecome a MemberLogin          
Papers of the Week
Current Papers
ARF Recommends
Milestone Papers
Search All Papers
Search Comments
News
Research News
Drug News
Conference News
Research
AD Hypotheses
  AlzSWAN
  Current Hypotheses
  Hypothesis Factory
Forums
  Live Discussions
  Virtual Conferences
  Interviews
Enabling Technologies
  Workshops
  Research Tools
Compendia
  AlzGene
  AlzRisk
  Antibodies
  Biomarkers
  Mutations
  Protocols
  Research Models
  Video Gallery
Resources
  Bulletin Boards
  Conference Calendar
  Grants
  Jobs
Early-Onset Familial AD
Overview
Diagnosis/Genetics
Research
News
Profiles
Clinics
Drug Development
Companies
Tutorial
Drugs in Clinical Trials
Disease Management
About Alzheimer's
  FAQs
Diagnosis
  Clinical Guidelines
  Tests
  Brain Banks
Treatment
  Drugs and Therapies
Caregiving
  Patient Care
  Support Directory
  AD Experiences
Community
Member Directory
Researcher Profiles
Institutes and Labs
About the Site
Mission
ARF Team
ARF Awards
Advisory Board
Sponsors
Partnerships
Fan Mail
Support Us
Return to Top
Home: News
News
News Search  
Nano-Imagery: Synchrotron Shows Iron Hiding Out in Dopamine Vesicles
5 October 2007. A new technique that allows researchers to see the subcellular distribution of iron and other metals in neurons reveals that dopamine-containing neurotransmitter vesicles may function as iron storage depots. The implication is that perturbations in iron-dopamine interactions could contribute to the death of dopaminergic neurons in Parkinson disease, possibly by an increase in oxidative stress.

Consistent with a role for oxidative stress in the disease, another new study shows that the protein products of two different Parkinson-causing genes interact in a single pathway that protects cells against mitochondrial stress, and which appears altered in both sporadic and familial PD.

In the first paper, Richard Ortega and colleagues at Bordeaux University in Gradignan, France, tracked down iron in cells courtesy of a powerful, highly focused X-ray beam emanating from the European Synchrotron Radiation Facility in Grenoble, France. Because of the intense brightness of the beam and the high resolution of the images (down to 90 nm), the researchers were able for the first time to detect iron florescence in subcellular compartments of rat PC12 cells. They found iron mainly in dopamine-containing neurotransmitter vesicles. Overloading cells with iron increased the vesicular signal, particularly in neurite outgrowths and distal ends of the cells. Depleting the cells of dopamine caused a decrease in vesicular iron.

Dysfunctional iron metabolism has been implicated not only in Parkinson disease, but also in other neurodegenerative conditions. Published online in PLoS ONE on September 26, the new method will be generally useful for studying the distribution of iron and other metals in models of these diseases, the authors write. See open-access paper for X-ray fluorescence pictures of iron in dopamine cells.

Iron is essential for normal brain function. Local increases in brain or neuronal iron have been associated with PD, Alzheimer’s, and other neurodegenerative conditions (Oakley et al., 2007; Collingwood et al., 2005). Iron accumulation may even be useful as a biomarker for early PD: an ultrasound signal indicating high iron in the brain region affected by PD has been documented before cells begin to die off. The technique is now being tested as a clinical marker for early PD (Peng et al., 2007). Excess iron could cause increased oxidative damage, a pathway implicated in neurodegeneration generally. However, understanding exactly what iron is doing depends on knowing where it accumulates in cells.

In the new work, Ortega and colleagues first looked at iron distribution in normal dopamine-producing PC12 cells. They observed 200 nm cytosolic structures that contained most of the iron in the cell. Loading cells with additional iron increased the fluorescence associated with the vesicles. The scientists then went on to show that the vesicles also contained dopamine. When the researchers inhibited dopamine synthesis in the cells, the iron content of the vesicles decreased—results that are consistent with an iron-storage function for dopamine. The authors hypothesize that lowered dopamine or faulty storage of the neurotransmitter, both of which have been observed in PD, could raise levels of highly oxidizing cytosolic iron or iron-dopamine complexes, to the detriment of neurons. The researchers saw no such specific localization or changes in potassium or zinc distribution, which they measured with the same technique.

Blaming toxicity on excess iron or highly oxidizing iron-dopamine complexes fits with the idea that death of neurons in PD stems from oxidative stress. In further support of that notion, new work from the labs of Miguel Martins of the MRC in Leicester, UK, and Julian Downward at the Cancer Research UK London Research Institute, demonstrates that the protein product of PINK1, a putative mitochondrial kinase encoded at the PARK6 locus, associates with the apoptotic protease HtrA2 (encoded by the PARK13 gene). PINK1 appears necessary for the phosphorylation of HtrA2 after stimulation of the stress-activated p38 map kinase pathway, and loss of function of either protein sensitizes cells to oxidative stress. Thus, HtrA2, a protein previously proposed to be proapoptotic, appears to help protect cells from mitochondrial stress.

The work, published in the September 30 online issue of Nature Cell Biology, suggests that both proteins contribute resistance to apoptosis in response to mitochondrial stress. Thus, the protective effect recently discovered for PINK1 (Pridgeon et al., 2007 and see review by Abeliovich, 2007) may come at least in part from its ability to modulate HtrA2 activity.

PINK1 mutations cause rare, early-onset Parkinson disease, but the PINK1/HtrA2 pathway could play a role in the more frequent, sporadic form of PD as well, the authors claim. Looking at patient tissue, the investigators found that the phosphorylation of HtrA2 is decreased in patients with early-onset PD due to PINK1 mutations. However, the opposite occurs in sporadic PD, where HtrA2 phosphorylation is increased. Since phosphorylation appears to make HtrA2 more active, the results raise the possibility that HtrA2 is activated as a compensatory response to ongoing stress in sporadic PD, and that further understanding of this pathway could yield insights and novel therapeutic approaches to the most common form of the disease.—Pat McCaffrey.

References:
Ortega R, Cloetens P, Deves G, Carmona A, Bohic S. Iron Storage within Dopamine Neurovesicles Revealed by Chemical Nano-Imaging. PLoS ONE. 2007 Sep 26;2(9):e925. Abstract

Plun-Favreau H, Klupsch K, Moisoi N, Gandhi S, Kjaer S, Frith D, Harvey K, Deas E, Harvey RJ, McDonald N, Wood NW, Martins LM, Downward J. The mitochondrial protease HtrA2 is regulated by Parkinson's disease-associated kinase PINK1. Nat Cell Biol. 2007 Sep 30; [Epub ahead of print] Abstract

 
Comments on News and Primary Papers
  Primary Papers: Iron storage within dopamine neurovesicles revealed by chemical nano-imaging.

Comment by:  Julie Andersen
Submitted 5 October 2007  |  Permalink Posted 5 October 2007

This is significant in that it provides a new analytical tool for spatially assessing the presence of iron in cells including neurons. Although iron has been reported to be increased in the substantia nigra, the brain region impacted in the disorder, information on cell-specific and/or subcellular localization has been lacking. That is where this group’s finding that iron is present in dopaminergic neurons is most significant for Parkinson disease. When dopamine synthesis was reduced, this resulted in release of iron-dopamine complexes from neurovesicles into the cytoplasm. Release of dopamine from the vesicles could result in increased oxidation, leading to enhanced cell death. This study was performed in the dopaminergic cell line PC12 neuronally differentiated via nerve growth factor. I am not familiar enough with the technique to assess its possible clinical applications (it appears it might only be useful for analyses of postmortem samples), but it does appear as if it would be useful in terms of assessing subcellular iron localization at least in animal models of the disease.

View all comments by Julie Andersen

  Primary Papers: The mitochondrial protease HtrA2 is regulated by Parkinson's disease-associated kinase PINK1.

Comment by:  George Perry (Disclosure)
Submitted 15 October 2007  |  Permalink Posted 16 October 2007
  I recommend this paper

  Primary Papers: Iron storage within dopamine neurovesicles revealed by chemical nano-imaging.

Comment by:  Joanna Collingwood
Submitted 17 October 2007  |  Permalink Posted 17 October 2007

Comment by Joanna Collingwood, Jon Dobson, Mark Davidson, Chris Batich, Albina Mikhaylova, and Jeff Terry
This interesting study by Ortega et al. uses a high-resolution synchrotron X-ray probe in a newly developed configuration at the European Synchrotron Radiation Facility (ESRF). The technique they describe has, in recent years, been embraced by researchers from the medical community. It is good to see facility expansion and development in this area as synchrotron X-ray chemical imaging is adopted as a valuable technique to study biological samples (e.g., Mikhailova et al., 2000; Mikhaylova et al., 2005; Wang et al., 2005; Collingwood et al., 2005; Palmer et al., 2006; McRae et al., 2006; Chwiej et al., 2007; Arora et al., 2007).

Ortega et al. have achieved an excellent in-plane resolution of 90 nm to map iron, zinc, and potassium. Although subcellular chemical mapping studies are conducted at below 50 nm at facilities such as the Advanced Photon Source (APS) 2-ID beamline, mapping in the hard energy range used by Ortega et al. has usually been performed at...  Read more

  Submit a Comment on this News Article
Cast your vote and/or make a comment on this news article. 

If you already are a member, please login.
Not sure if you are a member? Search our member database.

*First Name  
*Last Name  
Country or Territory:
*Login Email Address  
*Password    Minimum of 8 characters
*Confirm Password  
Stay signed in?  

I recommend the Primary Papers

Comment:

(If coauthors exist for this comment, please enter their names and email addresses at the end of the comment.)

References:


*Enter the verification code you see in the picture below:


This helps Alzforum prevent automated registrations.

Terms and Conditions of Use:Printable Version

By clicking on the 'I accept' below, you are agreeing to the Terms and Conditions of Use above.
Print this page
Email this page
Alzforum News
Papers of the Week
Text size
Share & Bookmark
ADNI Related Links
ADNI Data at LONI
ADNI Information
DIAN
Foundation for the NIH
AddNeuroMed
neuGRID
Desperately

Antibodies
Cell Lines
Collaborators
Papers
Research Participants
Copyright © 1996-2013 Alzheimer Research Forum Terms of Use How to Cite Privacy Policy Disclaimer Disclosure Copyright
wma logoadadad